Histone deacetylase inhibitors open new doors in cancer therapy

McLaughlin, F. and La Thangue, N.B. (2004) Histone deacetylase inhibitors open new doors in cancer therapy. Biochemical Pharmacology, 68, pp. 1139-1144. (doi: 10.1016/j.bcp.2004.05.034)

Full text not currently available from Enlighten.

Abstract

Cancer drug development has moved from conventional cytotoxic chemotherapeutics to a more mechanism-based targeted approach towards the common goal of tumour growth arrest. The rapid progress in chromatin research has supplied a plethora of potential targets for intervention in cancer. Here, we focus on the histone deacetylase (HDAC) inhibitors, together with their current status of clinical development and potential utility in cancer therapy. HDACs have been widely implicated in growth and transcriptional control, and inhibition of HDAC activity using small molecules causes apoptosis in tumour cells. We discuss the rationale for the development of HDAC inhibitors as novel anti-cancer agents, the potential clinical application and explore ideas on how we may move towards patient stratification with the possibility of increasing efficacy in the clinic.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:UNSPECIFIED
Authors: McLaughlin, F., and La Thangue, N.B.
College/School:College of Medical Veterinary and Life Sciences
Journal Name:Biochemical Pharmacology

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
103261Molecular and functional charactersation of the cell cycle regulating DP and E2F transcription factorsNicholas La ThangueMedical Research Council (MRC)G9400953Biochemistry & Cell Biology